stockrow
Friday 6 November 2026
Export ADMA’s income statement to Excel — free account
ADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
13.03
0.18
−1.36%
Follow ADMA
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
29.90 | 20.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 7 | 6 | 5 | 4 | 2 | 4 | 2 | 3 | 4 |
P/S ratio |
8.52 | 9.37 | 3.95 | 4.97 | 2.43 | 3.98 | 7.41 | 6.36 | 3.32 | 5.68 |
Altman Z-Score |
19.98 | 18.78 | 2.74 | 1.29 | (0.84) | (1.51) | (1.79) | (4.05) | (1.70) | (6.43) |
P/FCF ratio |
158.03 | 36.31 | 252.94 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
8.80 | 6.18 | 0.29 | (0.07) | (0.95) | (2.44) | (5.00) | (9.62) | (3.16) | (16.91) |
Beneish M-Score |
(0.17) | 0.13 | (2.52) | (2.93) | (17.73) | — | — | — | — | (2.63) |
P/Operating CF |
121.96 | 79.60 | 57.91 | (103.78) | (5.88) | (5.21) | (11.06) | (5.75) | (5.66) | (16.75) |
P/B ratio |
9.11 | 11.45 | 7.54 | 5.04 | 1.39 | 1.90 | 8.30 | 5.46 | 1.87 | 0.00 |
Price to Tangible BV |
9.19 | 11.59 | 7.77 | 5.19 | 1.45 | 2.04 | 11.15 | 8.83 | 2.36 | 0.00 |
EV/Sales |
8.50 | 9.32 | 4.29 | 5.41 | 3.07 | 4.96 | 9.38 | 7.46 | 3.19 | 5.40 |
EV/EBITDA |
21.66 | 26.89 | 34.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
86.02 | 33.50 | 125.95 | (14.00) | (2.21) | (2.05) | (3.61) | (2.02) | (1.95) | (3.15) |
EV/FCF |
157.61 | 36.11 | 275.09 | (11.35) | (1.97) | (1.83) | (3.44) | (1.96) | (1.82) | (3.14) |
Quick Ratio |
3.54 | 2.76 | 1.58 | 2.60 | 2.62 | 3.47 | 2.15 | 2.51 | 4.98 | 1.45 |
Current Ratio |
6.71 | 5.97 | 5.16 | 6.89 | 6.87 | 7.71 | 6.12 | 4.63 | 6.60 | 1.93 |
Net Debt/EBITDA |
(0.06) | (0.15) | 2.75 | (2.23) | (1.00) | (0.70) | (1.56) | (0.33) | 0.08 | (0.19) |
Debt/Assets |
12.17% | 16.55% | 42.64% | 44.06% | 37.04% | 46.85% | 66.67% | 46.65% | 37.23% | 77.89% |
Debt/Equity |
0.16 | 0.23 | 1.04 | 1.01 | 0.72 | 1.10 | 3.23 | 2.10 | 1.00 | (4.14) |
Asset Turnover |
0.92 | 1.04 | 0.76 | 0.49 | 0.33 | 0.25 | 0.27 | 0.17 | 0.35 | 0.45 |
Operating CF/Net income |
0.34 | 0.60 | (0.31) | 0.90 | 1.57 | 1.35 | 1.58 | 0.95 | 0.85 | 0.94 |
Capex/Depreciation |
(2.64) | (0.97) | (0.46) | (1.48) | (1.86) | (2.28) | (0.89) | (0.48) | (0.80) | (0.07) |
Interest Coverage |
26.93 | 9.98 | 0.86 | (2.04) | (4.47) | (5.42) | (4.61) | (10.92) | (11.96) | (7.74) |
| 35.56% | 81.65% | (19.67%) | (44.96%) | (62.46%) | (132.38%) | (210.08%) | (218.77%) | (243.95%) | 1,073.35% | |
| 26.40% | 48.34% | (8.33%) | (21.10%) | (29.61%) | (45.25%) | (44.71%) | (66.78%) | (66.45%) | (82.34%) | |
ROIC |
25.69% | 26.58% | 6.03% | (11.23%) | (18.96%) | (31.30%) | (30.76%) | (97.92%) | (65.63%) | 0.00% |
Return on Tangible Assets |
31.80% | 59.80% | (10.82%) | (22.77%) | (31.25%) | (43.19%) | (46.63%) | (101.11%) | (52.49%) | (156.94%) |
Average Days of Receivables |
113.35 | 42.79 | 38.76 | 36.73 | 128.86 | 114.44 | 43.15 | 29.92 | 62.22 | 34.85 |
Research and Development Expense of Revenue |
0.93% | 0.43% | 1.28% | 2.35% | 4.50% | 13.99% | 7.99% | 23.11% | 24.47% | 72.12% |
Selling, General and Administrative Expense of Revenue |
17.95% | 17.38% | 22.86% | 34.05% | 53.00% | 83.02% | 88.28% | 132.48% | 82.39% | 79.68% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.05 | 0.08 | 0.08 | 0.00 |
Share Based Compensation of Revenue |
3.93% | 3.19% | 2.40% | 3.38% | 4.31% | 6.76% | 9.03% | 13.09% | 6.86% | 11.73% |
Graham Net Nets |
0.07 | 0.05 | 0.06 | 0.10 | 0.37 | 0.20 | (0.07) | (0.23) | (0.07) | (0.11) |
Graham Number |
5.24 | 5.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.66 |
Earnings Yield |
3.34% | 4.90% | (2.86%) | (8.79%) | (37.59%) | (45.13%) | (22.50%) | (61.09%) | (57.26%) | (32.53%) |
Free Cash Flow Yield |
0.63% | 2.75% | 0.40% | (9.59%) | (63.96%) | (68.30%) | (36.80%) | (59.98%) | (52.87%) | (30.31%) |
Revenue per Share |
2.14 | 1.83 | 1.15 | 0.78 | 0.58 | 0.49 | 0.54 | 0.38 | 0.99 | 0.88 |
Operating CF per Share |
0.21 | 0.51 | 0.04 | (0.30) | (0.81) | (1.18) | (1.40) | (1.39) | (1.63) | (1.50) |
Capex per Share |
(0.10) | (0.04) | (0.02) | (0.07) | (0.10) | (0.15) | (0.07) | (0.05) | (0.12) | (0.01) |
Free Cash Flow per Share |
0.12 | 0.47 | 0.02 | (0.37) | (0.90) | (1.33) | (1.47) | (1.43) | (1.74) | (1.51) |
Cash per Share |
0.37 | 0.44 | 0.23 | 0.44 | 0.37 | 0.65 | 0.49 | 0.50 | 1.88 | 1.26 |
Shareholders Equity per Share |
2.00 | 1.50 | 0.60 | 0.77 | 1.01 | 1.02 | 0.48 | 0.44 | 1.76 | (0.37) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.00 | 1.50 | 0.60 | 0.77 | 1.01 | 1.02 | 0.48 | 0.44 | 1.76 | (0.37) |
Free Cash Flow |
27.51 | 110.10 | 3.82 | (73.42) | (125.88) | (114.73) | (80.01) | (64.77) | (39.95) | (18.34) |
Working Capital |
396.97 | 275.87 | 207.21 | 231.14 | 178.35 | 133.79 | 71.79 | 34.90 | 52.90 | 10.43 |
Capital Expenditures |
(22.89) | (8.57) | (4.98) | (13.91) | (13.51) | (12.72) | (3.81) | (2.10) | (2.68) | (0.07) |
Net Current Asset Value |
319.59 | 191.75 | 63.04 | 73.92 | 73.65 | 34.32 | (15.08) | (24.58) | (5.34) | (6.49) |
EV/EBIT |
22.64 | 28.60 | 51.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.04 | 0.02 | 0.02 | 0.09 | 0.17 | 0.30 | 0.13 | 0.12 | 0.12 | 0.01 |
Price to Operating Income |
22.70 | 28.76 | 47.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | 0.16 | 0.20 | 0.16 | 0.14 | 0.13 | 0.14 | 0.15 | 0.11 | 0.50 |
Cash ROIC |
4.29% | 20.65% | 1.17% | (18.73%) | (42.73%) | (47.51%) | (58.11%) | (77.12%) | (32.31%) | (62.61%) |
Accounts Receivable Turnover |
4.90 | 11.02 | 12.03 | 6.99 | 3.87 | 5.05 | 12.07 | 6.44 | 9.29 | 10.98 |
Accounts Payable Turnover |
10.17 | 11.53 | 11.72 | 9.26 | 6.79 | 6.05 | 5.24 | 7.14 | 6.87 | 2.73 |
Inventory Turnover |
1.15 | 1.21 | 1.01 | 0.83 | 0.77 | 0.91 | 1.10 | 2.70 | 3.31 | 1.50 |
Average Days of Payables |
37.81 | 35.67 | 33.77 | 40.64 | 56.87 | 65.95 | 84.77 | 51.04 | 74.10 | 147.17 |
Days of Inventory on Hand |
346.63 | 300.32 | 372.83 | 501.60 | 570.69 | 485.56 | 490.29 | 161.04 | 158.05 | 288.07 |
Average Receivables |
104.21 | 38.71 | 21.46 | 22.04 | 20.91 | 8.35 | 2.43 | 2.64 | 2.45 | 0.97 |
Average Payables |
21.37 | 17.94 | 14.44 | 12.83 | 11.75 | 10.12 | 7.54 | 5.91 | 4.24 | 2.33 |
Average Inventory |
188.35 | 171.57 | 168.09 | 144.00 | 103.13 | 67.30 | 35.84 | 15.62 | 8.82 | 4.23 |
Average Assets |
556.46 | 408.93 | 338.82 | 312.36 | 241.96 | 167.38 | 107.98 | 98.45 | 65.85 | 23.70 |
Average Common Equity |
413.17 | 242.11 | 143.59 | 146.57 | 114.71 | 57.22 | 22.98 | 30.05 | 17.94 | (1.82) |
Columns are period end dates · fundamentals updated 4 Nov 2026